echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > JiMu Biological Suprachoroidal Injection Therapy ARVN001 Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India

    JiMu Biological Suprachoroidal Injection Therapy ARVN001 Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, China, August 15, 2021-Arctic Vision (hereinafter referred to as "Jimu" or "Jimu"), which focuses on innovative ophthalmic therapies, announced that it has partnered with Clearside Biomedical, Inc.


    Ten ASEAN countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam) and India

    ARVN001 is a patented suspension of the glucocorticoid triamcinolone acetonide, which can be administered to the suprachoroidal space (SCS®) through the patented suprachoroidal microinjector (SCS Microinjector®).


    Dr.


    Dr.


    Dr.


    About ARVN001

    ARVN001 is a patented suspension of the glucocorticoid triamcinolone acetonide for suprachoroidal injection and is being developed for the treatment of uveitis macular edema (UME)


    In March 2020, Jimu Biotech obtained the development and commercialization rights of XIPERE™ in Greater China (Mainland China, Hong Kong, Macau and Taiwan) and South Korea, with the project code ARVN001.


    ARVN001 has not yet been approved for marketing globally, and the US New Drug Marketing Application (NDA) was accepted by the FDA in May 2021


    About uveitis macular edema (UME)

    About uveitis macular edema (UME)

    Uveitis is a group of highly blinding ocular inflammatory diseases involving the uvea


    About JiMu Bio

    About JiMu Bio

    JiMu Bio is a biotechnology company headquartered in China, focusing on innovative ophthalmic therapies, with a series of breakthrough ophthalmic treatment technology product portfolios covering from the early detection stage to the commercialization stage


    About Clearside Biomedical

    About Clearside Biomedical

    Clearside Biomedical, Inc.


    JiMu Bio Media Contact:

    JiMu Bio Media Contact:

    communications@arcticvision.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.